The SWL clinical migraine drug pathway is based on national recommendations in line with NICE and BASH guidance and have been developed through collaboration between SWL ISPS and Once for London (NEL MMO) team in consultation with clinicians and relevant groups.
These guidelines aim to support clinicians to deliver enhanced patient care and improve outcomes in neurology patients with migraines.
This webpage is kept under review and reflects the latest guidance at the time of publication. It remains the responsibility of prescribers to ensure they adhere to the latest guidelines, license changes and product availability.